Radiopharm Theranostics Limited (ASX:RAD – Get Free Report) insider Riccardo Canevari purchased 684,787 shares of the business’s stock in a transaction on Monday, December 16th. The stock was acquired at an average price of A$0.03 ($0.02) per share, with a total value of A$19,858.82 ($12,411.76).
Radiopharm Theranostics Stock Performance
Radiopharm Theranostics Company Profile
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
Featured Stories
- Five stocks we like better than Radiopharm Theranostics
- What is the FTSE 100 index?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- About the Markup Calculator
- 2 Drone Stocks Surging from Increased Media Attention
- Financial Services Stocks Investing
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
